Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice

American Journal of Veterinary Research

Volumn 65, Issue 5, 2004, Pages 659-664

  Farese, James P ^a   Fox, Leslie E ^c   Detrisac, Carol J ^a   Van Gilder, James M ^a   Roberts, Sara L ^a   Baldwin, Jamie M ^b  

^a University of Florida College of Veterinary Medicine   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; THALIDOMIDE; ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GROWTH INHIBITION; HISTOPATHOLOGY; LOW DRUG DOSE; LUNG METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; OSTEOSARCOMA CELL; TREATMENT OUTCOME; TUMOR EMBOLISM; TUMOR GROWTH; TUMOR VOLUME; XENOTRANSPLANTATION; ANIMAL; ANIMAL DISEASE; CELL CULTURE; COMPARATIVE STUDY; DOG DISEASE; LUNG TUMOR; METASTASIS; PATHOLOGY; TIME;

ANIMALIA; CANIS FAMILIARIS; MUS MUSCULUS;

ANGIOGENESIS INHIBITORS; ANIMALS; DIMETHYL SULFOXIDE; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OSTEOSARCOMA; THALIDOMIDE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 3042524562     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.659     Document Type: Article

References (33)

1. Dernell WS, Straw RC, Withrow SJ. Tumors of the skeletal system. In: Withrow SJ, MacEwen EG, eds. Small animal clinical oncology. Philadelphia: WB Saunders Co, 2001;378-401.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
3. Tseng S, Pak G, Washenik K, et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-979.
4. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000; 108:487-495.
5. Zwingenberger K, Wnendt S. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations, J Inflamm 1995;46:177-11.
6. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-4085.
7. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998;55:1827-1834.
8. McBride WG. Thalidomide embryopathy. Teratology 1977;16:79-82.
9. Seifert R, Zhao B, Christ B. Cytokinetic studies on the aortic endothelium and limb bud vascularization in avian embryos. Anat Embryol (Berl) 1992;186:601-610.
10. Sheskin J. Further observation with thalidomide in lepra reactions. Lepr Rev 1965;36:183-187.
11. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-1058.
12. Jacobson JM, Spritzler J, Fox L, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. J Infect Dis 1999;180:61-67.
13. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997;350:1445-1446.
14. Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol 2001;28:577-582.
15. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341: 1565-1571.
16. Berenson JR, Bergsagel PL, Munshi N. Initiation and maintenance of multiple myeloma. Semin Hematol 1999;36:9-13.
17. Kotoh T, Dhar DK, Masunaga R, et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999;125:536-544.
18. Minchinton AI, Fryer KH, Wendt KR, et al. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996;7:339-343.
19. Mori S, Ueda T, Kuratsu S, et al. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 1995;61:148-152.
20. Nieves MA, Vahle J, Ackermann M, et al. Production and characterization of canine osteosarcoma cell lines that induce transplantable tumors in nude mice. Am J Vet Res 1998;59:359-362.
21. Hong SH, Kadosawa T, Mochizuki M, et al. Effect of all-trans and 9-cis retinoic acid on growth and metastasis of xenotransplanted canine osteosarcoma cells in athymic mice. Am J Vet Res 2000;61:1241-1244.
22. Barroga EF, Kadosawa T, Okumura M, et al. Establishment and characterization of the growth and pulmonary metastasis of a highly lung metastasizing cell line from canine osteosarcoma in nude mice. J Vet Med Sci 1999;61:361-367.
23. Kadosawa T, Nozaki K, Sasaki N, et al. Establishment and characterization of a new cell line from a canine osteosarcoma. J Vet Med Sci 1994;56:1167-1169.
24. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213-221.
25. Lienenluke B, Stojanovic T, Fiebig T, et al. Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat - role of endothelial cell-leukocyte interaction. Br J Pharmacol 2001;133:1414-1423.
26. Settles B, Stevenson A, Wilson K, et al. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol (Noisy-legrand) 2001;47:1105-1114.
27. Baatz H, Tonessen B, Prada J, et al. Thalidomide inhibits leukocyte-endothelium interaction in endotoxin-induced uveitis. Ophthalmic Res 2001;33:256-263.
28. Schneider J, Bruckmann W, Zwingenberger K. Extravasation of leukocytes assessed by intravital microscopy: effect of thalidomide. Inflamm Res 1997;46:392-397.
29. Higman MA, Port JD, Beauchamp NJ Jr, et al. Reversible leukoencephalopathy associated with re-infusion of DMSO preserved stem cells. Bone Marrow Transplant 2000;26:797-800.
30. McEntee MC. Radiation therapy in the management of bone tumors. Vet Clin North Am Small Anim Pract 1997;27:131-138.
31. Machak GN, Tkachev SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 2003;78:147-155.
32. Ramirez O, III, Dodge RK, Page RL, et al. Palliative radiotherapy of appendicular osteosarcoma in 95 dogs. Vet Radiol Ultrasound 1999;40:517-522.
33. Green EM, Adams WM, Forrest LJ. Four fraction palliative radiotherapy for osteosarcoma in 24 dogs. J Am Anim Hosp Assoc 2002;38:445-451.